MedTrace Logo

3 Days Versus 5 Days Amoxicillin for Chest-indrawing Childhood Pneumonia in Malawi

NCT02678195 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3000

Last updated 2021-02-18

No results posted yet for this study

Summary

This clinical trial evaluates the duration of treatment of chest-indrawing pneumonia in children. Half the children will receive 3 days of amoxicillin dispersible tablets (DT) and then 2 days of placebo, while the other half will receive 5 days of amoxicillin DT.

Conditions

Interventions

DRUG

Amoxicillin

Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily

DRUG

Placebo

Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily

Sponsors & Collaborators

  • University of North Carolina

    collaborator OTHER

  • University of Washington

    collaborator OTHER

  • Save the Children

    lead OTHER

Principal Investigators

  • Amy Ginsburg, MD, MPH · Save the Children

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Months
Max Age
59 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2019-04-30
Completion
2019-12-31

Countries

  • Malawi

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02678195 on ClinicalTrials.gov